June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Endoscopic Sinus Surgery Speeds Recovery

A retrospective study comparing endoscopic and traditional open sinus surgery for chronic rhinosinusitis with nasal polyps found shorter operative times, fewer complications, and improved outcomes associated with the endoscopic technique.

Conexiant

June 13, 2025

Lifestyle Interventions Recommended First-Line in Diabetes

A new guideline recommends using lifestyle interventions as first-line treatment to prevent, manage, and potentially reverse type 2 diabetes and prediabetes, supported by extensive clinical evidence.

Conexiant

June 13, 2025

The Special Series HPLC E-book

Are we still pushing the limits of liquid chromatography? Absolutely, say our experts – who continue to surf on the edge of LC innovation – as part of our special collection of recent HPLC insights.

The Analytical Scientist

June 12, 2025

Medical Oddities: 6 Foot Moves Possibly Worth Prescribing

Strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 12, 2025

Gary Patti: Metabolomics Is Not in Crisis

Our ability to measure and quantitate key metabolites remains robust, reproducible, and highly valuable – regardless of how the issue around unknowns plays out

The Analytical Scientist

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

June 12, 2025

Four Toxins Tested for Glabellar Wrinkle Duration

A new randomized trial using 3D imaging compared four botulinum toxin A formulations in women, revealing differences in onset and durability of glabellar wrinkle reduction over six months.

Conexiant